Added to YB: 2026-02-20
Pitch date: 2026-02-17
TMDX [bullish]
TransMedics Group, Inc.
-49.12%
current return
Author Info
No bio for this author
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$2.2B
Pitch Price
$135.33
Price Target
164.00 (+138%)
Dividend
N/A
EV/EBITDA
19.63
P/E
14.38
EV/Sales
4.12
Sector
Health Care Equipment and Supplies
Category
growth
Top Picks 2026: A Map of Opportunities in Transformational Markets | TransMedics Group, Inc. (TMDX) — Innovation in Organ Preservation
TMDX: Organ Care System leader, 10K+ transplants, targeting 20-30K by 2030. Heart/lung Phase 3 results due 2026, kidney Gen 3 launch early 2027. OrganOx acquisition validates category. $164 PT (+2.65% from $138.49), but upside if trials beat. Hold until Q1'26 earnings for clinical update.
Read full article (1 min)